



**BIOLABO**  
 www.biolabo.fr  
**MANUFACTURER:**  
**BIOLABO SAS,**  
 Les Hautes Rives  
 02160, Maizy, France

# TRIGLYCERIDES GPO Method

Reagent for quantitative determination of triglycerides  
 in human serum and plasma

I REF K1519	R1	4 x 17 mL
I REF K2519	R1	4 x 30 mL

## TECHNICAL SUPPORT AND ORDERS

Tel: (33) 03 23 25 15 50

support@biolabo.fr

Latest revision: www.biolabo.fr



Made In France

I: corresponds to significant modifications

## I INTENDED USE

This reagent is designated for professional use in laboratory (automated method). It allows the quantitative determination of triglycerides in human serum and plasma.

## I GENERALITIES (1)

The measurement of the concentration in blood triglycerides is important for the diagnosis and the follow-up of hyperlipidemia. Its increase can be of genetic origin or secondary to other metabolic disorders such as: diabetes mellitus, hyper and hypothyroidisms, hepatic diseases, acute and chronic pancreatitis, nephrosis. A rise in triglycerides also represents an atherogenic risk factor. It is responsible for the opalescence, or even the cloudiness of the serum. Corticoids and estrogen/progestin treatments can also aggravate hypertriglyceridemia.

## PRINCIPLE (4) (5)

Fossati and Prencipe method associated with Trinder reaction. Reaction scheme is as follows:



The absorbance of the colored complex (quinoneimine), proportional to the amount of triglycerides in the specimen, is measured at 500 nm.

## REAGENTS

R1	TG2	Reagent
		PIPES 100 mmol/L
		Magnesium chloride 9.8 mmol/L
		Chloro-4-phenol 3.5 mmol/L
		Lipase $\geq 1000$ IU/L
		Peroxidase (POD) $\geq 1700$ IU/L
		Glycerol 3 phosphate oxidase (GPO) $\geq 2000$ IU/L
		Glycerol Kinase (GK) $\geq 1000$ IU/L
		4 - Amino - antipyrine (PAP) 0.5 mmol/L
		Adenosine triphosphate Na (ATP) 1.3 mmol/L
		Clearing Agent 1.5 mmol/L

According to 1272/2008/EC Regulation, this reagent is not classified as dangerous.

## SAFETY CAUTIONS

- Refer to current Material Safety Data Sheet available on request or on www.biolabo.fr
  - Verify the integrity of the contents before use.
  - Waste disposal: Respect legislation in force in the country.
  - All specimens or reagents of biological origin should be handled as potentially infectious. Respect legislation in force in the country.
- I Any serious incident that has occurred in connection with the device is notified to the manufacturer and the competent authority of the Member State in which the user and/or patient is based.

## REAGENTS PREPARATION

Ready for use

## STABILITY AND STORAGE

Stored away from light, well capped in the original vial at 2-8°C, used and stored as described, reagents are stable:

Unopened:

- Until expiry date stated on the label.

Once opened:

- Reagent is stable at least 3 months.
- Discard any reagent if cloudy, in case of loss of sensitivity or if reagent blank is upper than 0.400 at 505nm.

This reagent must be refrigerated during transport.

## SPECIMEN COLLECTION AND HANDLING (2)

Serum or plasma (Heparin or EDTA) fasting  $\geq 12$  hours.

Separate from cells within 2 hours.

Do not use oxalate, fluoride or citrate.

Triglycerides are stable in specimen for:

- 5-7 days at 2-8°C.
- 3 months at -20°C.
- Many years at -70°C.

Avoid repeated freezing and thawing.

## LIMITS (3)

For a more comprehensive review of factors affecting this assay refer to the publication of Young D.S.

## MATERIAL REQUIRED BUT NOT PROVIDED

- Basic medical analysis laboratory equipment.
- Biochemistry Clinical Analyzer Kenza One, Kenza 240TX/ISE or Kenza 450TX/ISE

## EXPECTED VALUES (6)

Triglycerides	mg/dL	[ mmol/L ]
Reference range	35 -160	[ 0.40-1.82 ]

Each laboratory should establish its own normal ranges for the population that it serves.

## PERFORMANCES

On Kenza 240TX, at 37°C, 505 nm:

Linearity Range: between 10 and 1000 mg/dL

Detection limit: approx. 6 mg/dL

Precision:

Within-run N = 20	Low level	Normal level	High level	Between run N = 20	Low level	Normal level	High level
Mean (mg/dL)	55	136	262	Mean (mg/dL)	57	139	259
S.D. mg/dL	0.9	1.6	3.0	S.D. mg/dL	1.6	2.1	4.6
C.V. %	1.6	1.2	1.1	C.V. %	2.9	1.5	1.8

Comparison studies with commercially available liquid reagent:  
Realized on human specimens (n=103) between 21.9 and 526.3 mg/L  
 $y = 1.0139x - 2.4376$   $r = 0.9977$

Analytical sensitivity: approx. 0.0018 abs for 1 mg/dL

Interferences:

Total bilirubin	Negative interference from 238 µmol/L
Direct bilirubin	Negative interference from 90 µmol/L
Ascorbic acid	Negative interference from 304 mg/dL
Glucose	No interference up to 1064 mg/dL
Hemoglobin	Positive interference from 333 µmol/L
Free glycerol <sup>(1)(2)</sup>	Overestimation of approx. 10 mg/dL (0,11 mmol/L) due to endogen glycerol

Other substances may interfere (see § Limits)

On the board stability: 2 months

Calibration Stability: 2 months

Make a new calibration when changing reagent batch, if quality control results are found out of the established range and after maintenance operations.

Performances and stability data on Kenza 450TX/ISE and Kenza One are available on request.

## CALIBRATION (7)

- **REF** 95015 Multicalibrator traceable to Internal Masterlot

The calibration frequency depends on proper instrument functions and on the preservation of reagent.

## QUALITY CONTROL

- **REF** 95010 EXATROL-N Level 1
- **REF** 95011 EXATROL-P Level 2
- or
- **REF** 95516 Lipids Control serum Level 1
- **REF** 95526 Lipids Control serum Level 2
- External quality control program

It is recommended to control in the following cases:

- At least once a run
- At least once within 24 hours
- When changing vial of reagent
- After maintenance operations on the instrument

If control is out of range, apply following actions:

1. Prepare a fresh control serum and repeat the test
  2. If control is still out of range, use a new vial of fresh calibrator
  3. If control is still out of range, use a new vial of reagent and re-assay
- If control is still out of range, please contact BIOLABO technical support or your local Agent.

## PROCEDURE










Refer to validated application of the Kenza Analyzer used

## CALCULATION

The analyzer provides directly final result.  
Refer to the instruction of use of Kenza analyzer.

## REFERENCES

- (1) TIETZ N.W. *Text book of clinical chemistry*, 3<sup>rd</sup> Ed. C.A. Burtis, E.R. Ashwood, W.B. Saunders (1999) p. 809-857.
- (2) *Clinical Guide to Laboratory Test*, 4<sup>th</sup> Ed., N.W. TIETZ (2006) p. 1074-1077.
- (3) YOUNG D.S., *Effect of Drugs on Clinical laboratory Tests*, 4<sup>th</sup> Ed. (1995) p.3-573 to 3-589
- (4) Fossati P., Prencipe L., *Clin. Chem.* (1982), 28, p.2077-2080.
- (5) Trinder P. *Ann. Clin. Biochem.* (1969), 6, p.27-29.
- (6) TIETZ N.W. *Text book of clinical chemistry*, 2<sup>nd</sup> Ed. C.A. Burtis, E.R. Ashwood, W.B. Saunders (1994)p. 1030-1058 et p. 1073-1080.
- (7) SRM: Standard Reference Material ®

 Manufacturer <b>REF</b> Product Reference	 Expiry date  See Insert	 In vitro diagnostic <b>LOT</b> Batch number	 Storage temperature  Store away from light	 Dematerialized water  Sufficient for	 Biological risk → Dilute with
--	---	--	--	--	--